Biora Therapeutics (NASDAQ:BIOR) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Biora Therapeutics (NASDAQ:BIORFree Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock.

Biora Therapeutics Trading Down 1.0 %

BIOR stock opened at $0.73 on Thursday. The firm’s fifty day simple moving average is $0.83 and its two-hundred day simple moving average is $1.08. Biora Therapeutics has a twelve month low of $0.59 and a twelve month high of $6.70.

Biora Therapeutics (NASDAQ:BIORGet Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). Analysts anticipate that Biora Therapeutics will post -1 EPS for the current year.

Biora Therapeutics Company Profile

(Get Free Report)

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.

Featured Articles

Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.